CytoDyn Inc.
CYDY · OTCMCIK 1175680fmd_0WDE8N771Z2313TBBHGZNBH4JB制造业 · 医药制剂模板: 标准
覆盖范围: 2004年6月01日 至 2026年8月31日，共 72 个期间
| 项目 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | – | – | 0 | 0 | 0 | – | – | – |
| 营业成本 | – | – | – | – | – | 0 | – | – | – | – |
| 毛利润 | – | – | – | – | – | 0 | – | – | – | – |
| 研发费用 | 20 | 38 | 42 | 53 | 53 | 27 | 3 | 7 | – | – |
| 营业费用合计 | 27 | 46 | 56 | 75 | – | – | – | – | – | – |
| 营业利润 | (27) | (46) | (56) | (75) | (105) | (145) | (41) | (18) | 10 | (39) |
| 利息费用 | 1 | 6 | 3 | 65 | 72 | 65 | 39 | 32 | – | – |
| 利息及投资收益 | 0 | 0 | 0 | 0 | 0 | – | – | 0 | 1 | 0 |
| 税前利润 | (26) | (50) | (64) | (140) | (176) | (211) | (80) | (50) | 4 | (43) |
| 所得税费用 | 0 | 0 | (3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 持续经营净利润 | (26) | (50) | (61) | (140) | (176) | (211) | (80) | (50) | 4 | (43) |
| 净利润 | (26) | (50) | (61) | (140) | (176) | (211) | (80) | (50) | 4 | (43) |
| 归属于普通股股东的净利润 | – | – | – | (141) | (178) | (212) | (87) | (51) | 2 | (44) |